Omnicell, Inc. (OMCL) stock
Close on Nov 11, 2026Market cap $1.62BP/E 36.7Yield –
Omnicell, Inc. grew revenue 5.6% to $1.24B over the twelve months to Sep 30, 2026. Operating income rose 277.2% to $64.65M, moving the operating margin from 1.5% to 5.2%. Free cash flow was $145.77M, up 30.8% from a year earlier. At the latest close the market valued the company at $1.62B, 36.7 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.62B
- P/E ratio
- 36.7
- Price to sales
- 1.30
- Price to book
- 1.23
- Dividend yield
- –
- Free cash flow yield
- 8.98%
Fundamentals
- Revenue
- $1.24B
- Net income
- $44.67M
- EPS, diluted
- $0.97
- Free cash flow
- $145.77M
- Book value per share
- $28.35
- Diluted shares
- 46M
Trading
- Next earnings
- Feb 4, 2027 (estimated, before the open)
- Previous close
- $35.90
- Open
- $36.02
- Day's range
- $35.29 – $36.18
- Volume
- 418,421
- Average volume (20 days)
- 632,960
- Index membership
- S&P SmallCap 600 (since Nov 2023), Russell 2000, Russell 3000
- Beta (5 years)
- 0.83
- 52-week range
- $31.75 – $55.00
- RSI (14 days)
- 46.5
- Volatility (1 year)
- 49.9%
- Relative volume
- 0.64×
- WACC
- 9.1%
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | OMCL | S&P 500 | Difference | OMCL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.7% | -2.4% | +1.7 pts | ||
| 3 months | -3.5% | -1.2% | −2.3 pts | ||
| Year to date | -21.5% | +12.3% | −33.8 pts | ||
| 1 year | -4.1% | +12.4% | −16.6 pts | ||
| 3 years | +15.6% | +78.8% | −63.2 pts | +5.0% | +21.4% |
| 5 years | -80.1% | +75.2% | −155.2 pts | -27.6% | +11.9% |
| 10 years | +11.3% | +311.1% | −299.8 pts | +1.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Omnicell filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
About Omnicell
Electronic Computers
Omnicell develops healthcare technology and medication management systems. The company provides automated dispensing cabinets, central pharmacy robotics, intravenous sterile compounding systems, and medication adherence packaging equipment and supplies. It also offers technical and professional support, as well as software platforms such as the OmniSphere intelligence ecosystem and the EnlivenHealth patient engagement platform. Omnicell manages its business operations within a single reporting segment. Its customer base includes hospitals, health systems, institutional long-term care facilities, ambulatory clinics, and retail and outpatient pharmacies.
Company profile, executives and historyOmnicell stock: common questions
What is Omnicell's stock price?
OMCL closed at $35.57 on Nov 11, 2026, down 0.92% on the day. Over the past 52 weeks it traded between $31.75 and $55.00.
What is Omnicell's market cap?
Omnicell was worth $1.62B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is OMCL's P/E ratio?
OMCL trades at 36.7 times earnings, based on diluted earnings per share of $0.97 over the twelve months to Sep 30, 2026.
How much revenue does Omnicell make?
Omnicell reported revenue of $1.24B for the twelve months to Sep 30, 2026, up 5.6% from a year earlier.
Does Omnicell pay a dividend?
No. Omnicell has not paid a cash dividend over the last twelve months.
When does Omnicell report earnings next?
Omnicell is expected to report Q4 FY2026 results on Feb 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has OMCL stock performed over the past year?
Including dividends, OMCL returned -4.1% over the past year, against +12.4% for the S&P 500.
How many OMCL shares are sold short?
4M shares were sold short at the latest FINRA report, 8.56% of the float, or 6.3 days of average trading volume.
Who are Omnicell's competitors?
Companies most similar to Omnicell by business, industry and size include EXTR, DBD, PAR, VYX, PBI.
See a number that looks wrong?